Their model invokes a tumor cell surface pool of PDL1 (more sensitive to checkpoint inhibition) and an exosome pool of PDL1, which impacts T cell priming in lymph nodes that remains resistant to such therapies. This evidence concerns the gene CD274 and neoplasm.